VICL listed as buyout target in article posted today
Vical Incorporated (VICL): Vical researches and develops vaccine therapies for the prevention and treatment of cancer and other infectious diseases, with five active clinical and preclinical programs in development. Vical share prices have been fluctuating between $2.88 and $3.30 this month, with good news coming recently with European patent approval for treatment TransVax.
We're high on Vical's prospects because of its use of DNA vaccines, which offer less risk and more efficient manufacturing compared to traditional pathogen-induced vaccines. The technology allows Vical to provide vaccines in weeks instead of months or years without ever having to handle the pathogen.
Based on Vical's effective products in the pipeline, lack of debt, and reserves of cash to last it through 2012, we see Vical as a strong buy. We think shares could reach closer to $6 by year's end with initiation of Phase III trials for multiple drugs
in a seeking alpha article, found it as a link on one of the messages on the GERN message bd. No lie, I'm too lazy to write that much. They used old VICL trade prices I noticed, but article dated 5/18/2011